Making a difference, patient by patient

US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs

Patients are key to everything that we do at US WorldMeds


We will remain a sustainable, privately held specialty pharmaceutical company.


We will develop, license, and market meaningful and accessible healthcare products that improve lives and result in a thriving community of patients, employees, and shareholders.


We will embrace a culture that values honesty, creativity, and action, integrity in relationships, a passion for success, and good stewardship of Company resources. We will endeavor to develop, recognize, reward, and retain teammates who deliver results and embody our Vision and Mission.

Our people bring US WorldMeds to life

The leadership team at US WorldMeds

Paul Breckinridge "Breck" Jones
Chief Executive Officer

Founder and Member of the Board of Directors

H. Lee Warren, Jr
Chief Operating Officer

Over 25 years of experience in Pharmaceutical Operations, Sales Management, Marketing and National Accounts

George Digenis, PhD
Chief Scientific Officer

Professor Emeritus of Medicinal Chemistry at University of Kentucky College of Pharmacy

Henry van den Berg, MD
Senior Vice President

25 years of experience in Medical Affairs and Marketing

Stephanie Montgomery
Vice President, Finance

20 years of experience in Operational Accounting, Finance and Development

Kristen Gullo
Vice President, Development and Regulatory Affairs

Over 10 years of experience in Pharmaceutical Development Strategy, Clinical Operations and Regulatory Affairs

Robert Gilkin, RPh
Vice President, Commerical Operations and Market Access
Michael Brown
Associate General Counsel and Compliance Officer
Breck Jones, Jr
Managing Director, Recovery Business


Discover the latest news, featured stories, and past news from US WorldMeds

March 31, 2022 |

US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product

High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths

LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

Read more

-News Archives (Click)-